Research programme: anti-viral antibody therapeutics - Oncotelic Therapeutics
Latest Information Update: 30 Apr 2021
At a glance
- Originator Mateon Therapeutics
- Developer Oncotelic Therapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections; Viral infections
Highest Development Phases
- Research COVID 2019 infections; Viral infections
Most Recent Events
Development Overview
Introduction
Oncotelic Therapeutics (formerly Mateon Therapeutics) is developing monoclonal antibodies for the treatment of coronavirus infectious disease (COVID-2019) as well as other viral diseases occurring due to zoonotic viruses; under a rapid antiviral response programme. The company will also develop engineered antibodies based on antibodies derived from patients that have mounted a protective response to the COVID-2019 virus infection. The company will develop the therapeutics using its artificial intelligence platform; EdgePoint which processes machine learning models. Early research is underway in the US.
The anti-viral antibodies programme which is being developed under Rapid Antiviral Response Program will be modeled after the ongoing EdgePoint AI development model at Mateon. After developing and establishing the technology, Mateon plans to form a separate company or sell the technology and the programme to a larger entity for further development.
In March 2021, Mateon Therapeutics has acquired Oncotelic and then changed its name to Oncotelic Therapeutics [1] .
Key Development Milestones
In March 2020, Mateon Therapeutics reported that it is evaluating the potential of its AI Vision technology to help monitor patients infected with the COVID-19 virus, or any other viruses [2] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Antivirals, Monoclonal antibodies
- Target Virus replication
- Mechanism of Action Virus replication inhibitors
-
WHO ATC code
J05A-X (Other antivirals)
-
EPhMRA code
J5B (Antivirals, excluding anti-HIV products)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | - | Research | USA | Parenteral / unspecified | Oncotelic Therapeutics | 02 Mar 2020 |
| Viral infections | - | - | Research | USA | Parenteral / unspecified | Oncotelic Therapeutics | 02 Mar 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Mateon Therapeutics | Originator | USA |
| Oncotelic Therapeutics | Owner | USA |
Licensing Availability
| Licensing Organisation | Available Indication | Available Phase | Region | Date |
|---|---|---|---|---|
| Mateon Therapeutics | COVID 2019 infections, Viral infections | Unspecified | - | 02 Mar 2020 |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 30 Mar 2021 | Company Involvement | Mateon Therapeutics has acquired Oncotelic and then changed its name to Oncotelic Therapeutics Updated 30 Apr 2021 |
| 02 Mar 2020 | Licensing Status | Research programme: anti-viral antibody therapeutics - Mateon Therapeutics is available for licensing as of 02 Mar 2020. https://www.oncotelic.com/ Updated 12 Mar 2020 |
| 02 Mar 2020 | Phase Change | Early research in COVID-2019 infections in USA (Parenteral) [2] Updated 06 Mar 2020 |
| 02 Mar 2020 | Phase Change | Early research in Viral infections in USA (Parenteral) [2] Updated 06 Mar 2020 |
References
-
ONCOTELIC THERAPEUTICS, INC. (FORMERLY MATEON THERAPEUTICS, INC.) NAME AND SYMBOL CHANGE.
Media Release -
Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG